Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221580 | 1.00 | MEN1 (0.61) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL1970335 | 1.00 | MEN1 (0.61) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL30923180 | 0.95 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL56905 | 0.91 | MAPT (0.53) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL13820 | 0.91 | MAPT (0.53) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL1968766 | 0.91 | MAPT (0.53) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL23727584 | 0.89 | HPGD (0.57) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL12205292 | 0.89 | HPGD (0.57) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL7853341 | 0.86 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL4526338 | 0.86 | MEN1 (0.56) | MEN1KMT2AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646532-B | A kind of synthetic method of diaza spiro [5.6] dodecane of 2 tertbutyloxycarbonyl, 10 carbonyl, 8 oxo 2,11 | 上海药明康德新药开发有限公司 | 2017-07-28 | — | — | CN | claimed |
| CN-105646532-A | Synthesis method of 2-tertbutyloxycarbonyl-10-carbonyl-8-oxo-2,11-diazaspiro[5.6]dodecane | 上海药明康德新药开发有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-104592215-A | Preparation method of piperidine-substituted oxadiazole derivative | Hunan huateng pharmaceutical co ltd | 2015-05-06 | — | — | CN | claimed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| EP-4593836-A2 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | Board of Regents, The University of Texas System (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | disclosed |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | ADDEX PHARMA SA (CH) | 2009-08-13 | — | — | US | disclosed |
| EP-1912979-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1,2,4]OXADIAZOL-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2008-04-23 | — | — | EP | disclosed |
| EP-1893606-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-05 | — | — | EP | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007039781-A2 | NEW COMPOUNDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006123255-A2 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006123257-A2 | PHENYL-3-{(3-(1H-PYRROL-2-YL)-[1, 2 , 4]0XADIAZ0L-5-YL]PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2004002483-A1 | SUBSTITUTED 3- AND 4- AMINOMETHYLPIPERIDINES FOR USE AS BETA-SECRETASE IN THE TREATMENT OF ALZHEIMER’S DISEASE | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | MEN1 1308/4885KMT2A 148/4885ALDH1A1 2352/4885 |
| US-20260062407-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX3, PRDX2 | MEN1 4804/4885KMT2A 4417/4885ALDH1A1 748/4885 |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | MEN1 1149/4885KMT2A 1611/4885ALDH1A1 4067/4885 |
| US-20250289818-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER | SLC10A1, SLC6A6, SLC10A6 | MEN1 517/4885KMT2A 3610/4885ALDH1A1 841/4885 |
| US-20090203737-A1 | Pyrrole Derivatives as Positive Allosteric Modulators of Metabotropic Receptors | GRM5, GRIK5, GRM2 | MEN1 4289/4885KMT2A 2493/4885ALDH1A1 4261/4885 |
| US-20250243209-A1 | HETEROCYCLES AS MODULATORS OF NSD ACTIVITY | NSD3, NCOA1, NR1D1 | MEN1 4039/4885KMT2A 2045/4885ALDH1A1 3935/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | MEN1 3803/4885KMT2A 2813/4885ALDH1A1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.